Q4 2024 Earnings Call Transcript February 4, 2025 Amgen Inc. beats earnings expectations. Reported EPS is $5.31, expectations ...

James Bradner; Executive Vice President - Research and Development; Amgen Inc Peter Griffith ... In oncology, our leading bispecific T-cell engager platform provides further opportunities for ...

My name is Julianne, and I will be your conference facilitator today for Amgen's fourth quarter and full year 2024 financial results conference call. All lines have been placed on mute to prevent ...

Amgen is a biotechnology leader with competitive advantages in scale, R&D, manufacturing efficiency, and distribution, bolstered by a robust pipeline and rising margins. I currently rate Amgen as ...

Biotechnology specialist Amgen (NASDAQ:AMGN) reported fourth-quarter and full-year 2024 earnings on Tuesday, Feb. 4, that topped analysts' consensus estimates. Analysts estimated Q4 adjusted EPS ...

Less than a decade since it secured its first FDA approval for a biosimilar, Amgen’s portfolio of the copycat drugs is growing and making strong contributions to the company’s top line.

Free cash flow surged to $4.4 billion, up a remarkable 1,367% year over year. Amgen reported strong fourth-quarter earnings, driven by strategic acquisitions and robust product sales growth.

RBC Capital analyst Gregory Renza maintained a Buy rating on Amgen (AMGN – Research Report) yesterday and set a price target of $320.00. The company’s shares closed yesterday at $289.02.

All of a sudden, Amgen stock is up 15% since late December to around $299. Its rise helped push up the healthcare sector up just over 7% since hitting a bottom in late December. The better-than ...

James Bradner; Executive Vice President - Research and Development; Amgen Inc Peter Griffith ... In oncology, our leading bispecific T-cell engager platform provides further opportunities for growth, ...

The FDA has started a priority review of Amgen’s tarlatamab for small cell lung cancer (SCLC), the lead drug in the company’s pipeline of bispecific T-cell engager (BiTE) drugs for solid tumours.